• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Late Stage Trial Focus Could Be A Game Changer For Relay Therapeutics (RLAY)

    Simply Wall St·11/12/2026 06:26:13
    Listen to the news
    • Relay Therapeutics reported third quarter 2026 results with revenue of US$3.35 million, a net loss of US$81.75 million, and a basic loss per share from continuing operations of US$0.37, while also posting a larger net loss of US$238.74 million for the first nine months of the year.
    • Despite lower revenue than the prior year period and continued losses, Relay Therapeutics is funding late stage oncology and vascular anomaly programs that form the core of its long term business plan, including Phase 3 work. These programs are intended to reshape how its pipeline supports future commercialization.
    • We will look at how Relay Therapeutics' investment narrative evolves as continued net losses intersect with the execution of late stage cancer trials.

    Scan biotech opportunities with similar late stage potential by reviewing the 19 high quality undiscovered gems that could be pricing in ambitious pipelines like Relay Therapeutics.

    Relay Therapeutics Investment Narrative Recap

    To own Relay Therapeutics, you need to be comfortable backing a business that is still deeply in investment mode and funding large clinical programs with limited current revenue. The analyst consensus Narrative on Simply Wall St centers on zovegalisib across breast cancer and vascular anomalies, so the latest quarterly loss mainly reinforces that Relay is still spending to progress these registrational studies.

    The recent report showed a third quarter net loss of US$81.75 million and a nine month loss of US$238.74 million, which keeps the focus squarely on execution risk. The key short term catalyst remains data and milestones from the Phase 3 ReDiscover 2 trial. The biggest operational risk is that these outcomes or regulatory interactions fall short while cash burn stays high.

    The third quarter and nine month earnings release is the clearest reference point for Relay Therapeutics right now. Management reported revenue of US$3.35 million for the first nine months of 2026 alongside sizeable continuing losses, which underlines how dependent the story is on pipeline progress rather than existing commercial activity.

    For you as a shareholder, that update feeds directly into the trial and cash runway questions highlighted in the analyst consensus Narrative on Simply Wall St. Large losses with limited top line contribution keep pressure on zovegalisib data, regulatory discussions in vascular anomalies and timing on future Phase 3 starts. Execution on those programs and disciplined use of capital are the practical milestones to watch.

    Relay Therapeutics' narrative projects US$117.0 million revenue and US$20.2 million earnings by 2029. This assumes revenue growing at 124.4% per year and an earnings swing of about US$306.2 million from earnings of negative US$286.0 million today.

    Uncover why Relay Therapeutics' fair value indicates a 40% potential upside to its current price that could narrow quickly.

    NasdaqGM:RLAY 1-Year Stock Price Chart
    NasdaqGM:RLAY 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most bullish analysts on Relay Therapeutics lean heavily on the vascular anomalies catalyst. Before this earnings update, they were pencilling in revenue of about US$170.5 million and earnings of roughly US$29.4 million by 2029, which is much more optimistic than consensus. You can compare those views and decide which assumptions feel realistic as fresh quarterly data and conference commentary filter through and potentially reshape each storyline.

    Explore another Relay Therapeutics fair value estimate, including one that suggests as much as 43% upside from the current price.

    Form Your Own Verdict

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking For More Ideas Beyond Relay Therapeutics?

    Once you have a view on Relay Therapeutics, it can help to compare that story with other opportunities that match your risk tolerance and time horizon. The Simply Wall St Screener lets you quickly filter for different profiles so you can line up Relay against a broader watchlist that fits your own approach.

    • If you want to focus on quality at a discount, start with a curated pool of 32 high quality undervalued stocks that pair fundamental strength with pricing that some investors may see as attractive.
    • For readers who care about capital preservation first, consider a set of 30 resilient stocks with low risk scores that score well on resilience and balance sheet strength.
    • If income is a priority, round out your research with a group of 6 dividend fortresses that offer higher yields while still passing key financial checks.